Zosano Pharma — Investor Presentation (April 2015)
31 slides from Zosano Pharma's investor presentation, Apr 15, 2015
Slide 1: Corporate Presentation April 2015
Exhibit 99.1 Corporate April 2015Presentation
Slide 2: Forward-Looking Statements
Forward-Looking This development further our candidates technologies “anticipate,” constitute to SEC incorrect. associated Although reflected assume 1circumstances differ expectations presentation onpossible no March materially in Actual we guarantees with obligation or forward-looking “design,” and
Slide 3: Zosano Pharma Investment Highlights
Zosano Investment Differentiated Capable Convenient Well ZP-PTH ZP-Glucagon GLP-1 Robust January 2Includes validated analogues IP Pharma 2015 of net (teriparatide) and delivering Highlights and proceeds IPO for transdermal life pipeline (ZSAN) easy-to-use: severe for cycle andtype of small entering
Slide 4: Development Pipeline
Development De-risked Preclinical Daily Severe ZP-Glucagon Osteoporosis Weekly Migraine ZP-Triptan Type Therapeutic Multiple 3Undisclosed 2ZP-PTH hypoglycemia diabetes GLP-1 Efficient programs Phase advantages Pipeline Portfolio 1pathways Phase withprovided prioritized high 2 Phase to price-per-unit
Slide 5: Future Pipeline Opportunities and Technical Screening Criteria
Future Technical Screening Compounds Preclinical Daily Weekly BNP Desmopressin es euGlucagon M hGH Octreotide Partnership Epinephrine Fentanyl ecules RWJ-445167 Influenza 4Vaccines cl Cyclosporin ol EPOadvantage Exenatide Preferably PTH Granisetron Pipeline PTH market case-by-case Plasmid Diphtheria
Slide 6: 2014 Achievements
2014 A ZP-Patch Signed Critical Completed Discussion Preclinical Solidified Embarked 5IPO Successful included inEli Novo advancement Review validation funding on Lilly and ZP-Glucagon with Foundational Nordisk concurrent a formulation successful partnership FDA and through of mid-2014 partnership ca
Slide 7: 2015 Outlook and Expected Milestones
2015IND Expected Confirm Establish Complete File Initiate Prepare Commence 6Discuss Outlook Phase for Phase Phase in significant to Phase Phase H2 Be3232015 aby & 2clinical Transformational 231by YE Phase of and clinical Q3 ZP-PTH ZP-Glucagon ZP-Triptan 2015 complete trial 2015 3 development study d
Slide 8: Convenient and Easy-to-Use Drug Delivery System
Zosano Pharma 7Convenient and Drug Easy-to-Use Delivery System
Slide 9: Rapid Onset Hydrophilic Microneedles
Rapid Onset Zosano Hydrophilic Microneedles 8Formulation Pharma approach drug quickly and areDrug High provides 200-350 formulation dissolved Delivery Bioavailability microns rapid coated by System onset interstitial long on –tips close of fluid microneedles proximity for shorttoTmax capillary bed
Slide 10: Zosano Formulations Show Higher Stability
Zosano Formulations Higher Dry, Demonstrated Phase 95 100 (%) Forteo 085 80 9Storage 5ZP-PTH 10 uhydrophilic rity 215 RT product Pharma Time Zosano 20 90325 PStable (months) yr 36 PT stability, Drug 30 PTH RT formulation month H 35 Stable at40 Delivery 40 Room shelf mcg longer Forteo of vs. Temperat
Slide 11: Eli Lilly Collaboration Deal Overview
Overview Deal $15 $125 Zosano 10 Confidential million terms million grants responsible to of be with equity ZP-PTH upon exclusive exclusive significant investment sales forCollaboration financing supplier milestones global pre-launch inlicensing ofprivate and commercial Double-digit with achieving v
Slide 12: ZP-PTH Phase 2 Trial Design
6Phase 165 Daily Primary Secondary N 40mcg 30mcg Screening ZP-PTH Randomization 20mcg Forteo 0Placebo 11month Month = post-menopausal 165 ZP-PTH dose, 2qd Trial endpoint: Primary/Secondary multi-national 1 Month endpoint: patient Design Patch ZP-Patch 2Increase self-administered Month Increase for w
Slide 13: ZP-PTH Pharmacokinetic Profile Comparable to Forteo
Daily Pulsatile Achieved Variability PK 12 HOURS OVER ZP-PTH Delivery dose in TIME patch Patch proportionate MEAN Critical doses Program—PK AUC comparable forand Building BYpulsatile DOSE Profile toBone Forteo pharmacokinetics injectable
Slide 14: ZP-PTH Higher BMD Gains vs. Forteo
Daily Higher HIP Increase BMD 3.470% 1.331% 0.138% 0.553% 2.960% (0.330%) *ZP-PTH Ref: 13vs.BMD Cosman ZP- Forteo ZP-PTH (%) Hip 3.550% 0.094% in ZP-PTH Placebo 20µg BMD SPINE Increase BMD 95% etPatch 30µg al Placebo (%) CI ZP-PTH 95% Gains BMD JCEM, in =4.970% Program 40µg 0.077 CIvs. 2010 =FORTEO
Slide 15: ZP-PTH Next Steps
Daily Next Agreement Phase Manufacturing Establish Single, Larger Trial Primary Six No 14 long-term month size: Steps ZP-PTH 3and active-comparator clinical endpoint: significant 400 safety longer forfracture postmenopausal Phase for infrastructure trial extension version non-inferior Osteoporosis d
Slide 16: ZP-Glucagon Potential for Severe Hypoglycemia
ZP-Glucagon Potential Severe Ease-of-use Underpenetrated Only Current Dry Efficient Clinical 15 powder two hypoglycemia glucagon development clinical to glucagon Expand critical needs for market development Severe injections toproducts for Highly be expected isthird-party life-threatening, reconstit
Slide 17: Current Treatment vs. Zosano Solution
Treatment Current Currently Complex, Significant Unstable Short 16 shelf Products formulation Marketed multi-step Time life prepafter Critical time NotProduct reconstitution reconstitution, Fast, Stable, User-Friendly forsimple, Emergency Zosano dry patch No no Press-and-Apply Solution prep reconsti
Slide 18: ZP-Glucagon Formulation Purity and Stability
Formulation Purity 98 99 100 97 096 95 ZP-Glucagon 171Formulation 2 3Formulation 4 5 6 Stability 7data Patch Months C 40C D demonstrates CStability 25C aFormulation Significant % stability Competitive D 25C over sixAdvantage months at room and elevated temperatures
Slide 19: ZP-Glucagon Short Tmax Phase 1 PK Data
ZP-Glucagon Short 20 Patch +/- 18 pg/ml subjects 4.4Tmax, C,min) upper tested High –arm Phase in Bioavailability (Tmax five-way 1 PK=Data 6.9 crossover +/- vs. and2.4 Injection Low min) study Variability Patch C, Across forearmDoses (Tmax = 8.1 +/- 3.9 min) Patch C, abdomen (Tmax = 8.4 +/- 3.4 min)
Slide 20: ZP-Glucagon Glucose Response Comparable to Injection
ZP-Glucagon All Patch 19 mmol/l Patch C, upper Doses –arm Phase With Patch Comparable 1 Glucose C, forearm Data PDPatch vs. to Injection Injection C, abdomen Patch D, abdomen IM glucagon injection
Slide 21: ZP-Glucagon Next Steps
ZP-Glucagon Next Launch FDA induction Develop 20 Steps feedback Gen Gen of hypoglycemia 12for product received product Severe using using regarding Hypoglycemia (16 reusable single-use patients) development applicator commenced applicator planand (also in integrated Q1with 2015coated Phase patchdose
Slide 22: ZP-Triptan Highly Suited for Acute Migraine
ZP-Triptan Highly Potential Comparable Self-administration Large, US 21 $1.9growing Suited billion best-in-class for orfor Migraine better total market Acute provides migraine onset rapid with Condition of onset: attractive significant action market Tmax Requiring than ($1.1 unit advantage =existing
Slide 23: ZP-Triptan Demonstrated High Bioavailability and Rapid Onset
ZP-Triptan Demonstrated 1,200 1,400 ,.8ng/mL Zolmitriptan 0600 200 Time, AUC ZP-Triptan1 IV 1. 22 0030 3cm2 Patch 1.26 60 Abs min 1,000 90 1patches 203 BA 120 for 1.81 400 % +/- High Migraine 150 coated Route 927296 180 Bioavailability 1,103 Dose with +/- +/- 106 800mcg (mg/kg) 92 587 N/A with +/- /
Slide 24: ZP-Triptan Rapid Onset vs. Other Products
Rapid ZP-Triptan Nasal ZP-Triptan(4) T Pain (H:MM) 2max Products (Ave) (1) (2) overall (6) the 23hours (Ave)(5) Average 53% Nasal: Oral—Tablets: same Relief /Onset average Oral 63% 75% Included: triptan. Imitrex With To relief Oral Associated 57% Melt(1) be ofPotential Patch at evaluated (sumatripta
Slide 25: ZP-Triptan Next Steps
ZP-Triptan Next Launch Single/multi Multiple Phase Expected Primary 24 Steps 1 product 2 development trial endpoint: patch tofor compare with dose Migraine doses using 200 crossover reduction with three to current patients commence zolmitriptan ZP-Triptan study inapplicator planned headache versus Q
Slide 26: Novo Nordisk Once-Weekly GLP-1 Collaboration
Once-Weekly 2014 Worldwide Novo Up Reimbursement 25 toVictoza Nordisk $60 million collaboration sales GLP-1 partnered responsible oftotal all = approximately Analog Zosano for program onfor first multiple Patch development allproduct commercialization with for $2 Novo potential Type billion and GLP-
Slide 27: ZP-Patch Intellectual Property
ZP-Patch Patent Issued & Transdermal 7Formulation/ Micro 4Design 5Patch 3Retainer 26US, PTHApplicator 1Projection 2 4 3Protection Patents & JP EU, Ring Intellectual Packaging Skin 235Coating/PK/PD & JP (owned Delivery Mfg Until Technology Property && 2027 ZP licensed) ControlPlatform = 22 US, Anchor
Slide 28: Zosano Pharma Milestones Summary
Zosano Lead Product Daily ZP-PTH Safety End-of-Phase Exclusive ZP-Glucagon Completed Rapid Feedback ZP-Triptan Short GLP-1 $60 Novo 27 million Product Tmax, •to onset, and •Completed Pharma Completed fund Signed trial received licensing efficacy 20 •milestones; high Completed vs. development Candida
Slide 29: Financial Highlights Post-IPO
Financial Post-IPO January Includes in Revenue Cash Debt 1. 2015 28 Cash millions (12/31/14)1 IPOand 2015 net $2.9 cash Highlights and 2014 cash proceeds IPO $4.3 concurrent sufficient 2013 equivalents $22.1 $1.2 and R&Dof concurrent to $15.0 $11.0 private fund balance, million $7.6 operation placem
Slide 30: Zosano Pharma Investment Highlights
Zosano Investment Differentiated Capable Convenient Well ZP-PTH ZP-Glucagon GLP-1 Robust January Includes 29 validated analogues IP Pharma 2015 of net (teriparatide) and delivering Highlights and proceeds IPO for transdermal life pipeline (ZSAN) easy-to-use: severe for cycle andtype of small enterin
Slide 31: Corporate Presentation April 2015
Corporate April 2015Presentation